Research location

Valparaíso

Chile

Published trials30

Site observations30

Linked trials published30

Page1 / 1

Research activity in Valparaíso

Chile

CureCurrent currently publishes aggregate city-level research activity for this location: 30 trials and 30 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Valparaíso

30 linked trials · page 1 of 1

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT05878769 · 2023-06-28 · 1 site observation

ACTIVE_NOT_RECRUITING

Pictograms to Facilitate Comprehension of Medical IndicationsNCT05609760 · 2022-08-01 · 1 site observation

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseNCT05037929 · 2021-10-05 · 1 site observation

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)NCT04636801 · 2021-07-14 · 1 site observation

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)NCT04636814 · 2021-07-12 · 1 site observation

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117 · 2020-10-19 · 1 site observation

ACTIVE_NOT_RECRUITING

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 AgonistNCT02808819 · 2016-06-30 · 1 site observation

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)NCT02465567 · 2015-06-30 · 1 site observation

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABANCT02258542 · 2014-11-19 · 1 site observation

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS TherapyNCT02075255 · 2014-04-28 · 1 site observation

Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 AgonistNCT01914757 · 2013-08-01 · 1 site observation

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerNCT01566721 · 2012-05-17 · 1 site observation

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor TherapyNCT01437566 · 2011-10-01 · 1 site observation

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisNCT01247324 · 2011-08-31 · 1 site observation

A Safety and Efficacy Study of Tralokinumab in Adults With AsthmaNCT01402986 · 2011-08-01 · 1 site observation

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic AsthmaNCT01290887 · 2011-06-01 · 1 site observation

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic AsthmaNCT01287039 · 2011-04-01 · 1 site observation

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung CancerNCT01263886 · 2011-02-01 · 1 site observation

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate CancerNCT01193244 · 2010-10-01 · 1 site observation

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)NCT01147250 · 2010-06-01 · 1 site observation

A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive DisorderNCT01034995 · 2010-02-01 · 1 site observation

Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic BronchitisNCT00656747 · 2008-03-01 · 1 site observation

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung CancerNCT00630110 · 2008-02-01 · 1 site observation

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast CancerNCT00553410 · 2007-08-01 · 1 site observation

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DNCT00490139 · 2007-05-16 · 1 site observation

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard ChemotherapyNCT00338286 · 2006-03-02 · 1 site observation

STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent AsthmaNCT00252824 · 2005-07-01 · 1 site observation

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic BronchitisNCT00473460 · 2004-10-01 · 1 site observation

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseNCT00099242 · 2003-11-01 · 1 site observation

Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast CancerNCT00022516 · 2000-11-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.